

Poster presentation

Open Access

PI9-55 LB. Effective control of a pathogenic SIVmac239 challenge by a novel heterologous mucosal prime and intramuscular boost vaccine strategy

Z Chen^{*1}, C Sun², Y Du¹, L Chen² and L Zhang³

Address: ¹AIDS Institute, The University of Hong Kong LKS Faculty of Medicine, Hong Kong, PR China, ²Guangzhou Institute of Biomedicine and Health, Chinese Academy of Science, Guangzhou, Guangdong, PR China and ³Comprehensive AIDS Research Center, Tsinghua University; AIDS Research, Beijing, PR China

* Corresponding author

from AIDS Vaccine 2009
Paris, France. 19-22 October 2009

Published: 22 October 2009

Retrovirology 2009, 6(Suppl 3):P419 doi:10.1186/1742-4690-6-S3-P419

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P419>

© 2009 Chen et al; licensee BioMed Central Ltd.

Background

The failure of a recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 in a phase 2b efficacy study in humans calls for efforts to develop novel vaccination strategies.

Methods

In this study, we developed a recombinant replication-competent modified vaccinia Tianan (MVT), namely rMVT_{SIVgpe}, as a mucosal vaccine expressing SIVmac Gag, Pol and Env. The immunogenicity and efficacy of rMVT_{SIVgpe} was studied in combination with an rAd5-based vaccine rAd5_{SIVgpe} in Chinese macaques (*Macaca mulatta*) without the protective MHC class I allele Mamu-A*01. rMVT_{SIVgpe} was given through intranasal and oral inoculations whereas rAd5_{SIVgpe} was given through intramuscular injection. Four macaques in each of the four study groups received the following prime and boost vaccinations: rMVT_{SIVgpe}/rAd5_{SIVgpe}; rMVT_{SIVgpe}/rAd5_{SIVgpe} twice; rAd5_{SIVgpe}/rAd5_{SIVgpe}; and placebo controls, respectively.

Results

We found that the heterologous rMVT_{SIVgpe}/rAd5_{SIVgpe} regimen elicited cellular immune responses with enhanced magnitude, breadth, sustainability, and poly-functionality when compared with the homologous rAd5_{SIVgpe} regimen. Higher levels of neutralizing antibody (Nab) responses were also induced by the rMVT_{SIVgpe}/

rAd5_{SIVgpe} regimen. These Nab responses, however, neutralized SIVmac1A11 but not SIVmac239. The additional round of rMVT_{SIVgpe}/rAd5_{SIVgpe} vaccinations did not enhance the immune responses further. After intrarectal challenge with a pathogenic and Chinese macaque-adapted SIVmac239 (5×10^5 TCID₅₀ per animal), one of four monkeys vaccinated with the rMVT_{SIVgpe}/rAd5_{SIVgpe} regimen was fully protected whereas the rest showed an average of 1.96 log and 2.22 log reduction of peak and set-point (6 weeks post challenge) viral loads as compared with control animals.

Conclusion

These data demonstrate that the rMVT_{SIVgpe}/rAd5_{SIVgpe} regimen induced durable partial immune control of a pathogenic, neutralization-resistant SIVmac239 challenge. Our findings have critical implications for further optimization of vaccination strategies against HIV-1 by engaging the mucosal immune system.